TO TABLE OF
Keeping you up to date on recent events across the nation and around the
loses defamation case
lawsuit brought by the makers of the potential CFIDS drug Ampligen against a
securities trader/short-seller was the subject of a July Philadelphia Inquirer
article. Author L. Stuart Ditzen chronicled trader Manuel Asensio’s charges of
stock fraud against Hemispherx Biopharma (HEB), as well as his efforts to force
down the price of its stock, which led Asensio and HEB to a Philadelphia
courtroom in February.
HEB’s lawsuit sought
$80 million from Asensio — the amount the company claims that Asensio’s
“hostile-adversarial” attack cost the company.
According to the
article, Asensio, known for his outrageous behavior, was repeatedly admonished
by the judge for violating and disrespecting the rules of the court. Asensio was
angered by the judge’s refusal to allow what he considered key evidence
supporting his opinion that Ampligen’s inventor, William A. Carter, “is engaged
in ‘one of the darkest medical stock scams in modern U.S. capital market
Despite the chaos
Asensio caused in the courtroom, the jury voted 11–1 in Asensio’s favor on Feb.
22. The jury decided that Asensio hadn’t caused any harm. But the beginning of
July the judge ordered a new trial, on the grounds that Asensio’s misconduct had
gone too far.
Ampligen’s Phase III
trial for the treatment of CFS continues. Over the past three years, 13 sites
around the country have been involved in the study. Ultimately, 230 CFS subjects
will be enrolled in the 64-week protocol, which is probably two years from
The U.S. Centers for Disease
Control and Prevention (CDC) has led an international, multi-disciplinary group
of researchers in exploring and recommending interim changes to the CFS case
definition, last updated in 1994.
William C. Reeves, MD,
lead CDC investigator for CFS, is the first author on a paper that offers
clarification of ambiguities found in the ’94 definition and suggests
measurement tools for assessing symptom severity and duration. The paper also
more clearly identifies permanent and temporary medical and psychiatric
exclusions that should be screened for before classifying a case as CFS.
Although the paper is
intended to enhance patient selection for and comparability of CFS research
studies, it offers recommendations that should be helpful to practicing
clinicians when considering a CFS diagnosis. The measurement tools listed can
also be useful in documenting functional impairment to support disability
The paper has been submitted to the
Annals of Internal Medicine.
publication date is yet available.
to discuss unique CFS, OI treatment
young Missouri man who suffers from chronic fatigue and orthostatic intolerance
(OI) has been asked to present his proposal for a treatment that may be useful
against some types of CFIDS and OI at a major research symposium this
D.M. Lindsay, who was
forced to leave college prior to graduation because of his illness, is scheduled
to speak at the American Autonomic Society’s 13th International Symposium on the
Autonomic Nervous System in October. He will discuss his scientific abstract
called, “Acute and Chronic Aspects of Dysautonomia Prompt Proposed Novel
treatment involves a novel combination of two drugs. One is currently used in
treating OI. The other, while currently contraindicated, may be of possible
benefit to a subset of sufferers, Lindsay says.
Lindsay hopes to find a
credentialed collaborator interested in testing his proposed treatment in a